Assessing the Potential Adoption of Psychedelic Medicine in Health Care Systems

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Pharmacy Times interviewed Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.

During the discussion, Ali addressed whether the adoption and acknowledgement of psychedelic medicine within health care systems looks likely for the future.

Related Content:

Brain HealthMental HealthNeurologyRetailHospital
Experts Express Concern About Lower Rates of Flu, Pneumococcal Vaccination Rates
Study Links New Type 1 Diabetes Diagnoses, Prior COVID-19 in Pediatric Patients
FDA Approves Diagnostic Test to Identify Patients with Metastatic Breast Cancer Expressing Low Levels of HER2 Protein